Management of Patients After IV Methylprednisolone Pulse Therapy

Introduction to Post-Pulse Care

The American College of Physicians recommends transitioning to oral prednisone at 1 mg/kg/day (maximum 60 mg/day) after pulsing a patient with IV methylprednisolone, and gradually tapering over 3-6 months depending on clinical response 1

The British Journal of Dermatology guidelines suggest that for pemphigus vulgaris, the oral prednisone dose should be initially reduced by 5-10 mg of prednisolone weekly and more slowly below 20 mg prednisolone daily 2, 4
The oral dose should not be reduced to less than 15 mg/day during the first 3 months of treatment in vasculitis, as recommended by the Praxis Medical Insights 1

The British Journal of Dermatology recommends considering adding a steroid-sparing agent such as azathioprine (1-3 mg/kg/day) for conditions like pemphigus vulgaris 4, 5
Azathioprine doses should be titrated according to individual activity of thiopurine methyltransferase (TPMT), as suggested by the British Journal of Dermatology 4

For pemphigus vulgaris, complete remission rates of 28-45% can be expected with appropriate adjunctive therapy, according to the British Journal of Dermatology 4
For severe neurological immune-related adverse events (irAEs), the Journal of Clinical Oncology recommends permanently discontinuing the immune checkpoint inhibitor after methylprednisolone pulse therapy 6
For immune-related pneumonitis, the Annals of Oncology suggests adding additional immunosuppressive agents like infliximab or mycophenolate mofetil if deterioration occurs under steroids 7
For lupus nephritis, the American Journal of Kidney Diseases recommends considering a regimen of reduced-dose glucocorticoids following methylprednisolone pulses when both kidney and extrarenal disease manifestations show satisfactory improvement 8
The American Journal of Kidney Diseases also suggests considering mycophenolic acid as maintenance therapy after pulse treatment for lupus nephritis 8